Results 151 to 160 of about 5,328 (181)
<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option. [PDF]
Transl Cancer ResRothschild SI, Mauti LA.
europepmc +1 more source
Durable Response in <i>NTRK</i> Fusion-Positive Advanced Salivary Gland Tumor: A Case Report. [PDF]
Case Rep OncolOblitas Alca GA +5 more
europepmc +1 more source
Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies. [PDF]
Cancers (Basel)Urtecho SB +3 more
europepmc +1 more source
Case report of entrectinib associated fulminant myocarditis. [PDF]
Eur Heart J Case RepRundhawa G +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Canadian Journal of Health Technologies, 2022
CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met ...
openaire +1 more source
CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met ...
openaire +1 more source